Literature DB >> 15847844

Multifocal motor neuropathy.

Jan-Thies H Van Asseldonk1, Hessel Franssen, Renske M Van den Berg-Vos, John H J Wokke, Leonard H Van den Berg.   

Abstract

Multifocal motor neuropathy (MMN) is an immune-mediated disorder characterised by slowly progressive, asymmetrical weakness of limbs without sensory loss. The clinical presentation of MMN mimics that of lower-motor-neuron disease, but in nerve-conduction studies of patients with MMN motor-conduction block has been found. By contrast with chronic inflammatory demyelinating polyneuropathy, treatment with prednisolone and plasma exchange is generally ineffective in MMN and even associated with clinical worsening in some patients. Of the immunosuppressants, cyclophosphamide has been reported as effective but only anecdotally. Various open trials and four placebo-controlled trials have shown that treatment with high-dose intravenous immunoglobulin leads to improvement of muscle strength in patients with MMN. Although clinical, pathological, imaging, immunological, and electrophysiological studies have improved our understanding of MMN over the past 15 years, further research is needed to elucidate pathogenetic disease mechanisms in the disorder.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15847844     DOI: 10.1016/S1474-4422(05)70074-0

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  24 in total

Review 1.  Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.

Authors:  Lotte Vlam; W-Ludo van der Pol; Elisabeth A Cats; Dirk C Straver; Sanneke Piepers; Hessel Franssen; Leonard H van den Berg
Journal:  Nat Rev Neurol       Date:  2011-11-22       Impact factor: 42.937

2.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 3.  [Plasma exchange as a therapeutic option in neurological disorders].

Authors:  H C Lehmann; H P Hartung; G R Hetzel; B C Kieseier
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

4.  Infliximab-associated neuropathy in RA patients--the importance of considering the diagnosis of mononeuritis multiplex.

Authors:  J Birnbaum
Journal:  Clin Rheumatol       Date:  2006-10-25       Impact factor: 2.980

5.  New liquid intravenous immunoglobulin (10 % IVIg) for treatment of multifocal motor neuropathy: a prospective study of efficacy, safety and tolerability.

Authors:  Elisabeth A Cats; W-Ludo van der Pol; Sanne Piepers; Nicoll C Notermans; R M van den Berg-Vos; L H van den Berg
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

Review 6.  Molecularly targeted therapies for dysimmune neuropathies.

Authors:  Andreas A Argyriou
Journal:  Mol Med       Date:  2009-05-05       Impact factor: 6.354

7.  [MR neurography for lesion localization in the peripheral nervous system. Why, when and how?].

Authors:  M Pham
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

8.  Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.

Authors:  Saiju Jacob; Yusuf A Rajabally
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 9.  Intravenous immunoglobulin treatment in multifocal motor neuropathy.

Authors:  W-Ludo van der Pol; Elisabeth A Cats; Leonard H van den Berg
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

10.  Multifocal motor neuropathy with abrupt onset and spontaneous recovery.

Authors:  Carel Bulens; Frédérique H Vermeij; Pieter A van Doorn
Journal:  J Neurol       Date:  2007-04-21       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.